Profiles
Professor Matthew Cramp
Chair in Hepatology
Biomedical Research - Institute of Translational & Stratified Medicine (Plymouth University Peninsula Schools of Medicine and De
Key publications are highlighted
Journals
Articles
2016
'Anti-envelope antibody responses in individuals at high risk of hepatitis C virus who resist infection'
Journal of Viral Hepatitis
23,
(11)
873-880
, DOI
2016
'Urinary Metabotyping of Hepatocellular Carcinoma in a UK Cohort Using Proton Nuclear Magnetic Resonance Spectroscopy'
Journal of Clinical and Experimental Hepatology
6,
(3)
186-194
, DOI
2015
'Diagnosis and management of hepatitis C'
British Journal of Hospital Medicine
76,
(11)
625-630
, DOI
2015
'Haplotype analysis finds linkage disequilibrium in the IL-12 gene in patients with HCV'
J Med Virol
87,
(7)
1207-1217
, DOI
2015
'HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact'
JOURNAL OF VIRAL HEPATITIS
22,
(4)
399-408
, DOI
PEARL
2015
'Implementation of the Lancet Standing Commission on Liver Disease in the UK'
The Lancet
386,
(10008)
2098-2111
, DOI
2014
'Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis'
Lancet
384,
(9958)
1953-1997
, DOI
2014
'Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis'
Lancet
384,
(9958)
1953-1997
2014
'CD81 sequence and susceptibility to hepatitis C infection'
JOURNAL OF MEDICAL VIROLOGY
86,
(1)
162-168
, DOI
2014
'Historical epidemiology of hepatitis C virus (HCV) in selected countries'
J Viral Hepat
21 Suppl 1,
5-33
, DOI
2014
'Impaired functional capacity in potential liver transplant candidates predicts short-term mortality before transplantation'
Liver Transpl
20,
(9)
1081-1088
, DOI
2014
'Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality'
BMC Gastroenterol
14,
, DOI
PEARL
2014
'Polymorphic differences in SOD-2 may influence HCV viral clearance'
J Med Virol
86,
(6)
941-947
, DOI
2014
'Role of Mycophenolate Mofetil for the Treatment of Autoimmune Hepatitis—An Observational Study'
Journal of Clinical and Experimental Hepatology
4,
(3)
221-225
, DOI
2014
'Strategies to manage hepatitis C virus (HCV) disease burden'
J Viral Hepat
21 Suppl 1,
60-89
, DOI
2014
'The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm'
J Viral Hepat
21 Suppl 1,
34-59
, DOI
2013
'Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts'
Ann Intern Med
158,
(4)
235-245
, DOI
2013
'Synergism of tapasin and human leukocyte antigens in resolving hepatitis C virus infection'
Hepatology
58,
(3)
881-889
, DOI
2012
'Cytokine profiles in high risk injection drug users suggests innate as opposed to adaptive immunity in apparent resistance to hepatitis C virus infection'
J Viral Hepat
19,
(7)
501-508
, DOI
2012
'POTENTIAL IMPACT OF PROTEASE INHIBITORS IN THE SOUTH WEST PENINSULA HEPATITIS C POPULATION'
GUT
61,
A140-A141
, DOI
2012
'Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis'
Eur J Gastroenterol Hepatol
24,
(5)
543-550
, DOI
2011
'A Polymorphism in IL28B Distinguishes Exposed, Uninfected Individuals From Spontaneous Resolvers of HCV Infection'
GASTROENTEROLOGY
141,
(1)
320-U419
, DOI
2011
'Loss of virus-specific T-cell responses in HCV exposed uninfected injection drug users with drug rehabilitation'
J Infect Dis
203,
(6)
847-853
, DOI
2011
'OP04 Synergistic influence of tapasin and HLA class I protection against chronic Hepatitis C virus infection'
Gut
60,
(Suppl 2)
A51-A52
, DOI
2011
'P45 Natural killer cell cytotoxicity is enhanced in injection drug users with apparent resistance to hepatitis C virus infection'
Gut
60,
(Suppl 2)
A21-A22
, DOI
2011
'P80 Patient characteristics and outcomes in a 'Hub and Spoke Model' for liver transplantation provision: The South West Liver Unit/King's College Experience'
Gut
60,
(Suppl 2)
A37-A37
, DOI
2011
'Treatment of autoimmune hepatitis: a review of current and evolving therapies'
J Gastroenterol Hepatol
26,
(4)
619-627
, DOI
2010
'Consistent Beneficial Effects of Killer Cell Immunoglobulin-Like Receptor 2DL3 and Group 1 Human Leukocyte Antigen-C Following Exposure to Hepatitis C Virus'
HEPATOLOGY
51,
(4)
1168-1175
, DOI
2010
'Limitations of the Algorithm for the SAFE Biopsy: A Noninvasive Fibrosis Measure in Chronic Hepatitis C'
HEPATOLOGY
51,
(1)
354-355
, DOI
2009
'ANTIVIRAL ACTIVITY AND SAFETY OF TMC435 COMBINED WITH PEGINTERFERON ALPHA-2A AND RIBAVIRIN IN PATIENTS WITH GENOTYPE 1 HEPATITIS C INFECTION WHO FAILED PREVIOUS IFN-BASED THERAPY'
JOURNAL OF HEPATOLOGY
50,
S385-S385
2009
'Elastography for the non-invasive assessment of liver disease: limitations and future developments'
GUT
58,
(8)
1171-1172
2008
'Interleukin 12B gene polymorphism and apparent resistance to hepatitis C virus infection'
Clin Exp Immunol
152,
(3)
538-541
, DOI
2008
'Surveillance of cirrhosis for hepatocellular carcinoma: a cost–utility analysis'
British Journal of Cancer
98,
(7)
1166-1175
, DOI
PEARL
2007
'Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis'
Health Technol Assess
11,
(34)
1-206
2006
'Case finding for hepatitis C in primary care: a cost utility analysis'
Fam Pract
23,
(4)
393-406
, DOI
2006
'Reactivation of latent hepatitis B virus infection with HIV-related immunosuppression'
Int J STD AIDS
17,
(1)
67-69
, DOI
2005
'Non-travel-associated Hepatitis C in England and Wales: Demographic, clinical, and molecular epidemiological characteristics'
Journal of Infectious Diseases
192,
(7)
1166-1172
2005
'Polymorphisms in the IL-12B gene and outcome of HCV infection'
J Interferon Cytokine Res
25,
(5)
271-276
, DOI
2004
'Direct evidence that naturally occurring mutations within hepatitis B core epitope alter CD4+ T-cell reactivity'
J Med Virol
72,
(3)
370-376
, DOI
2004
'HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection'
Science
305,
(5685)
872-874
, DOI
2004
'Screening for hepatitis C virus in the Dartmoor prison population: an observational study'
Journal of Public Health
26,
(4)
372-375
2003
'Liver histology and progression of fibrosis in individuals with chronic hepatitis C and persistently normal ALT'
AMERICAN JOURNAL OF GASTROENTEROLOGY
98,
(7)
1588-1593
, DOI
2003
'Liver histology and progression of fibrosis in individuals with chronic hepatitis C and persistently normal ALT'
Am J Gastroenterol
98,
(7)
1588-1593
, DOI
2003
'Traditional Chinese medicine in the treatment of chronic HCV infection'
Gut
52,
(5)
2002
'Acute hepatitis A virus infection: a review of prognostic factors from 25 years experience in a tertiary referral center'
Hepatogastroenterology
49,
(44)
524-528
2002
'Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases'
J Hepatol
36,
(2)
295-301
2002
'Interleukin-1, interleukin-10 and tumour necrosis factor-alpha gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to alpha-interferon therapy'
Liver
22,
(5)
404-412
2002
'Investigation and treatment of ascites'
Clin Med (Lond)
2,
(4)
310-313
2002
'Re: Whither smooth muscle antibodies in the third millennium?'
J Clin Pathol
55,
(7)
558-559
2001
'Liver transplantation in adults coinfected with HIV'
Transplantation
72,
(10)
1684-1688
2000
'Hepatitis C virus–specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C'
Gastroenterology
118,
(2)
346-355
, DOI
2000
'Liver histology and progression of fibrosis in individuals with chronic hepatitis C virus infection and persistently normal ALT'
HEPATOLOGY
32,
(4)
285A-285A
2000
'Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg)'
J Am Acad Dermatol
43,
(2 Pt 2)
403-408
1999
'HBV + HCV = HCC?'
Gut
45,
(2)
168-169
1999
'Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemia'
Gut
44,
(3)
424-429
1999
'The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre'
Gut
44,
(4)
563-567
, DOI
1998
'Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia'
J Hepatol
29,
(2)
207-213
1997
'Hepatitis in alcohol and drug misusers: practical issues'
Addiction Biology
2,
(4)
411-420
, DOI
1996
'Bile acid malabsorption in HIV infected patients with chronic diarrhoea'
Aust N Z J Med
26,
(3)
368-371
1996
'Seroprevalence of hepatitis B and C virus in two institutions caring for mentally handicapped adults'
J R Soc Med
89,
(7)
401-402
1994
'Cutaneous manifestations of mycobacterial infection in patients with AIDS'
Br J Dermatol
130,
(1)
111-114
1993
'Re-emergence of tuberculosis'
BMJ
306,
(6882)
1992
'Case report: pneumatosis intestinalis occurring in association with cryptosporidiosis and HIV infection'
Clin Radiol
46,
(6)
410-411
1992
'Rapid high-flux dialysis can cure uraemic peripheral neuropathy'
Nephrol Dial Transplant
7,
(6)
539-540
Conference Papers
2016
'C-ISLE: Grazoprevir/Elbasvir plus Sofosbuvir in Treatment-naive and Treatment-experienced HCV GT3 Cirrhotic Patients Treated for 8, 12 or 16 weeks'
//0
//0
39A-40A
2016
'Sofosbuvir plus Peginterferon plus Ribavirin for 12 Weeks in Genotype 3 HCV Infected Patients and Treatment-Experienced Cirrhotic Patients with Genotype 2 HCV Who Did Not Achieve SVR after 16 or 24 Weeks of Sofosbuvir plus Ribavirin'
//0
//0
455A-456A
2016
'Sustained viral clearance of HCV with DAA treatment is associated with restoration of effector T cell phenotype'
//0
//0
745A-745A
2015
'WARFARIN ANTICOAGULATION FOR LIVER FIBROSIS IN PATIENTS TRANSPLANTED FOR HEPATITIS C (WAFT-C): RESULTS AT ONE YEAR'
//0
//0
S268-S269
2014
'ALTERATIONS IN CXCR3/CXCL10 BUT NOT CCR5 IN HCV ARE ASSOCIATED WITH VIRAL INHIBITION WITH INTERFERON-FREE DIRECT ACTING ANTIVIRAL THERAPY'
//0
//0
S136-S136
2014
'High-Level Resistance to Hepatitis C - A Possible Role for Innate Immunity'
//0
//0
1064A-1064A
2014
'Neutralising anti-envelope antibodies in uninfected individuals that are repeatedly exposed to HCV'
//0
//0
1057A-1057A
2014
'REDUCING THE DISEASE BURDEN OF CHRONIC HEPATITIS C VIRUS (HCV) INFECTION IN ENGLAND'
//0
//0
S333-S334
2013
'ARE CURRENT TREATMENT RATES SUFFICIENT TO REDUCE HCV PREVALENCE AMONG PEOPLE WHO INJECT DRUGS? MODEL PROJECTIONS IN SEVEN UK SETTINGS'
//0
//0
S356-S356
2013
'THE USE OF CARDIOPULMONARY EXERCISE TESTING IN PREDICTING PRE- AND POST-OPERATIVE MORTALITY IN LIVER TRANSPLANT CANDIDATES'
//0
//0
S412-S412
2012
'HPS AND INTRAPULMONARY VASCULAR SHUNTS IN LIVER TRANSPLANT CANDIDATES'
//0
//0
S254-S254
2011
'ABSENCE OF IL-28B PROTECTION IN INDIVIDUALS EXPOSED TO HEPATITIS C VIRUS DEMONSTRATES DISCRETE GENETIC PATHWAYS FOR PROTECTION AGAINST CHRONIC HCV INFECTION'
//0
//0
S38-S39
2011
'NATURAL KILLER CELL CYTOTOXICITY IS ENHANCED IN INJECTION DRUG USERS WITH APPARENT RESISTANCE TO HEPATITIS C VIRUS INFECTION'
//0
//0
1322A-1322A
2011
'Synergistic influence of tapasin and HLA class I protection against chronic hepatitis C virus infection'
//0
//0
173-173
2010
'INDIVIDUALIZED CONCENTRATION MONITORED HIGH DOSE RIBAVIRIN IN COMBINATION WITH PEGINTERFERON TO HEPATITIS C GENOTYPE 1 PATIENTS WITH PREVIOUS NONRESPONSE'
//0
//0
710A-711A
2010
'PACIFIC: A PHASE III, RANDOMIZED, MULTICENTER, DOSE ESCALATION, EFFICACY AND SAFETY STUDY EXAMINING THE EFFECTS OF TREATMENT WITH PEGINTERFERON ALFA-2A IN PATIENTS WITH CHILD'S A OR B CIRRHOSIS IN CHRONIC HEPATITIS C VIRUS INFECTION'
//0
//0
710A-710A
2010
'PREDICTORS OF HEPATITIS C TREATMENT OUTCOME IN GENOTYPE 1 PATIENTS IN A "REAL WORLD" SETTING'
//0
//0
A77-A77
, DOI
2009
'ASSOCIATION OF HLA AND NK CELL INHIBITORY RECEPTOR WITH APPARENT RESISTANCE TO HEPATITIS C INFECTION'
//0
//0
386A-386A
2009
'CELLULAR DISTRIBUTION OF CLAUDIN 1 IN LIVER TISSUE IN HEPATITIS C AND OTHER LIVER DISEASES'
//0
//0
950A-950A
2009
'CYTOKINE PROFILES IN HCV EXPOSED BUT UNINFECTED CASES WITH APPARENT RESISTANCE TO HCV INFECTION'
//0
//0
936A-936A
2009
'LONGITUDINAL ANALYSIS OF HCV SPECIFIC T-CELL RESPONSES IN EXPOSED UNINFECTED INTRAVENOUS DRUG USERS'
//0
//0
S326-S326
2009
'LONGITUDINAL ANALYSIS OF HEPATITIS C VIRUS SPECIFIC T CELL RESPONSES IN EXPOSED UNINFECTED INTRAVENOUS DRUG USERS'
//0
//0
A17-A17
2008
'Audit of management of alcohol withdrawal at derriford hospital'
//0
//0
A72-A72
2008
'Hepatitis C virus (HCV)--specific T cell responses in injection drug users with apparent resistance to HCV infection'
United States
//0
//0
1749-1755
, DOI
2008
'Mycophenolate mofetil in patients with refractory autoimmune hepatitis'
//0
//0
A71-A72
2007
'HCV-specific cellular immune responses in intravenous drug users without HCV infection'
//0
//0
240A-241A
2007
'Interleukin 12B gene polymorphism and apparent resistance to HCV infection'
//0
//0
890A-891A
2007
'Single nucleotide polymorphism of the SRB1 gene and susceptibility to HCV infection'
//0
//0
A134-A135
2006
'Late spontaneous clearance of hepatitis C'
//0
//0
A43-A43
2005
'CD81 sequence and susceptibility to HCV infection'
//0
//0
A47-A47
2005
'HCV-specific cellular immune responses in subjects exposed to but uninfected by HCV'
//0
//0
A6-A7
2005
'HCV-specific cellular immune responses in subjects exposed, but uninfected by HCV'
//0
//0
A712-A712
PEARL
2004
'Endoscopic sphincterotomy is sufficient treatment for most post cholecystectomy bile leaks'
//0
//0
A44-A44
2003
'IL-12 gene polymorphism and outcome of HCV infection'
//0
//0
356A-356A
2003
'Specific antibody titres vary over time in individuals with chronic HCV infection and persistently negative HCV RNA'
//0
//0
2002
'Specific antibody titres vary over time in individuals with chronic HCV infection and persistently negative HCV RNA'
//0
//0
552A-552A
2002
'Traditional Chinese medicine in the treatment of chronic HCV infection'
//0
//0
569A-569A
Reports
2006
The cost-effectiveness of testing for hepatitis C in former injecting drug users.